RxDoctor Payments Data

David Bender, MD

Gynecologic Oncology · Iowa City, IANPI 1487641247

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,792 of the $2,984 with a category attached, or 60.1%. Intuitive Surgical accounts for 93.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $2,095 and has fallen 98.8% since, to $26 in 2025.

$2,984in general payments, 2019–2025

Across 21 payments — averaging $142.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Stryker$129
  • Covidien LP$52
  • Merck$26
$2,067,409in research payments, 2019–2025

Across 152 payments — averaging $13,601 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$893K
  • Tesaro, Inc.$432K
  • GSK$301K
  • Genentech, Inc.$197K
  • AbbVie$89K
  • Clovis Oncology, Inc.$77K
  • plus $78K from 2 others

What the payments were for

  • Travel & lodging$1,79260%
  • Food & beverage$93331%
  • Education$261%
  • Gifts$2338%

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical17$2,777
Stryker2$129
Covidien LP1$52
Merck1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few gynecologic oncology providers in Iowato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$75,821
Medicare patients
162
Services billed
410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Neomycin Sulfate12$66
Metronidazole13$35

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →